124 related articles for article (PubMed ID: 1906863)
1. Efficacy of once- and thrice-daily dosing of aminoglycosides in in-vitro models of infection.
Blaser J
J Antimicrob Chemother; 1991 May; 27 Suppl C():21-8. PubMed ID: 1906863
[TBL] [Abstract][Full Text] [Related]
2. Netilmicin: in-vitro activity compared with that of other aminoglycosides against Serratia marcescens.
Langstaff D; Schueler S; Righter J
J Antimicrob Chemother; 1983 Feb; 11(2):187-9. PubMed ID: 6339461
[TBL] [Abstract][Full Text] [Related]
3. Incorporation, release and in-vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa.
Omri A; Ravaoarinoro M; Poisson M
J Antimicrob Chemother; 1995 Oct; 36(4):631-9. PubMed ID: 8591937
[TBL] [Abstract][Full Text] [Related]
4. Interactions of antimicrobial drugs and combined phagocytic/serum bactericidal activity of defibrinated human blood against Serratia marcescens. II. Aminoglycosides: amikacin, gentamicin, and netilmicin.
Traub WH
Chemotherapy; 1982; 28(6):434-43. PubMed ID: 6761079
[TBL] [Abstract][Full Text] [Related]
5. Influence of pH on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides and their postantibiotic effects.
Xiong YQ; Caillon J; Drugeon H; Potel G; Baron D
Antimicrob Agents Chemother; 1996 Jan; 40(1):35-9. PubMed ID: 8787875
[TBL] [Abstract][Full Text] [Related]
6. A laboratory assessment of the activities of four aminoglycosides.
Schrire L; Robinson RG; Koornhof HJ
S Afr Med J; 1984 Jun; 65(23):922-4. PubMed ID: 6427946
[TBL] [Abstract][Full Text] [Related]
7. [Dosing aminoglycosides once a day].
Blaser J
Schweiz Med Wochenschr Suppl; 1996; 76():39S-48S. PubMed ID: 8677418
[TBL] [Abstract][Full Text] [Related]
8. Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia.
Weinstein RJ; Young LS; Hewitt WL
J Lab Clin Med; 1975 Nov; 86(5):853-62. PubMed ID: 810533
[TBL] [Abstract][Full Text] [Related]
9. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.
Blaser J; Stone BB; Groner MC; Zinner SH
Antimicrob Agents Chemother; 1987 Jul; 31(7):1054-60. PubMed ID: 3116917
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model.
Blaser J; Stone BB; Zinner SH
Antimicrob Agents Chemother; 1985 Mar; 27(3):343-9. PubMed ID: 3922294
[TBL] [Abstract][Full Text] [Related]
11. Once-daily versus multiple-daily dosing of aminoglycosides.
Craig WA
J Chemother; 1995 Jun; 7 Suppl 2():47-52. PubMed ID: 8622110
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the bactericidal action of amikacin, netilmicin and tobramycin in free and liposomal formulation against Pseudomonas aeruginosa.
Omri A; Ravaoarinoro M
Chemotherapy; 1996; 42(3):170-6. PubMed ID: 8983883
[TBL] [Abstract][Full Text] [Related]
13. [Antibacterial activities and PK/PD parameters of aminoglycosides against recent clinical isolates of gram-negative rods].
Okubo T; Iyobe S
Jpn J Antibiot; 2002 Oct; 55(5):514-23. PubMed ID: 12532635
[TBL] [Abstract][Full Text] [Related]
14. Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation.
Potel G; Caillon J; Fantin B; Raza J; Le Gallou F; Lepage JY; Le Conte P; Bugnon D; Baron D; Drugeon H
Antimicrob Agents Chemother; 1991 Jan; 35(1):111-6. PubMed ID: 2014965
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.
Tam VH; Ledesma KR; Vo G; Kabbara S; Lim TP; Nikolaou M
Antimicrob Agents Chemother; 2008 Nov; 52(11):3987-93. PubMed ID: 18725438
[TBL] [Abstract][Full Text] [Related]
16. In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model.
Bugnon D; Potel G; Xiong YQ; Caillon J; Kergueris MF; Le Conte P; Baron D; Drugeon H
Antimicrob Agents Chemother; 1996 May; 40(5):1164-9. PubMed ID: 8723459
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect.
Zhanel GG; Karlowsky JA; Hoban DJ; Davidson RJ
Chemotherapy; 1991; 37(2):114-21. PubMed ID: 1903340
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.
McGrath BJ; Lamp KC; Rybak MJ
Antimicrob Agents Chemother; 1993 Sep; 37(9):1931-7. PubMed ID: 8239608
[TBL] [Abstract][Full Text] [Related]
20. Invitro comparative evaluation of aminoglycosides at a cancer centre.
Biswas SK; Kelkar RS
Indian J Cancer; 2002; 39(4):135-8. PubMed ID: 12928571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
